Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy

Inclusion Criteria: * Subjects with non-myeloid malignancy * At least 12 additional weeks of cyclic cytotoxic chemotherapy anticipated regardless of schedule * Hemoglobin concentration less than 11.0 g/dL within 24 hours before randomization * Adequate serum folate and vitamin B12 * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 * Of legal age at the time written informed consent is obtained Exclusion Criteria: * Known history of seizure disorder * Known primary hematologic disorder causing anemia other than non-myeloid malignancies * Unstable/uncontrolled cardiac condition * Clinically significant inflammatory disease * Other diagnoses not related to the cancer which can cause anemia * Inadequate renal and liver function * Iron deficiency * Known positive test for HIV infection * Previously suspected of or confirmed to have neutralizing antibodies to rHuEPO * Received more than 2 red blood cell (RBC) transfusions within 4 weeks of randomization; or any RBC transfusion within 14 days before randomization; or any planned RBC transfusion between randomization and study day 1 * Received any erythropoietic therapy within 4 weeks of study day 1 or any planned erythropoietic therapy between randomization and study day 1 * Other investigational procedures * Currently enrolled in or has not yet completed at least 30 days since ending other investigational device or drug trial(s), or subject receiving other investigational agent(s) * Pregnant or breast feeding * Not using adequate contraceptive precautions * Previously randomized into this study * Known hypersensitivity to any products to be administered * Concerns for subject's compliance